1-1	0-14	Time‐dependent	_	_
1-2	15-23	neuronal	_	_
1-3	24-31	changes	_	_
1-4	32-42	associated	_	_
1-5	43-47	with	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
1-6	48-55	craving	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
1-7	56-58	in	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	_
1-8	59-65	opioid	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
1-9	66-76	dependence	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
1-10	76-77	:	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder
1-11	78-80	an	_	_
1-12	81-85	fMRI	_	_
1-13	86-91	study	_	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
1-14	92-100	Abstract	_	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
1-15	101-108	Relapse	_	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
1-16	109-114	after	_	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
1-17	115-124	initially	_	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
1-18	125-135	successful	_	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
1-19	136-145	treatment	_	http://maven.renci.org/NeuroBridge/neurobridge#ContinuousNondependentCocaineAbuse
1-20	146-148	is	_	http://maven.renci.org/NeuroBridge/neurobridge#ContinuousNondependentCocaineAbuse
1-21	149-150	a	_	http://maven.renci.org/NeuroBridge/neurobridge#ContinuousNondependentCocaineAbuse
1-22	151-162	significant	_	http://maven.renci.org/NeuroBridge/neurobridge#ContinuousNondependentCocaineAbuse
1-23	163-170	problem	_	http://maven.renci.org/NeuroBridge/neurobridge#ContinuousNondependentCocaineAbuse
1-24	171-177	facing	_	http://maven.renci.org/NeuroBridge/neurobridge#ContinuousNondependentCocaineAbuse
1-25	178-181	the	_	_
1-26	182-191	treatment	_	_
1-27	192-194	of	_	_
1-28	195-201	opioid	_	_
1-29	202-212	dependence	_	_
1-30	212-213	.	_	_

2-1	214-222	Evidence	_	_
2-2	223-231	suggests	_	_
2-3	232-239	craving	_	_
2-4	240-248	elicited	_	_
2-5	249-251	by	_	_
2-6	252-263	re‐exposure	_	_
2-7	264-266	to	_	_
2-8	267-271	drug	_	_
2-9	272-276	cues	_	_
2-10	277-280	may	_	_
2-11	281-292	precipitate	_	_
2-12	293-300	relapse	_	_
2-13	300-301	.	_	_

3-1	302-310	Attempts	_	_
3-2	311-313	to	_	_
3-3	314-322	identify	_	_
3-4	323-329	neural	_	_
3-5	330-340	biomarkers	_	_
3-6	341-343	of	_	_
3-7	344-356	cue‐elicited	_	_
3-8	357-364	craving	_	_
3-9	365-369	have	_	_
3-10	370-377	yielded	_	_
3-11	378-390	inconsistent	_	_
3-12	391-399	findings	_	_
3-13	399-400	.	_	_

4-1	401-403	We	_	_
4-2	404-409	aimed	_	_
4-3	410-412	to	_	_
4-4	413-418	apply	_	_
4-5	419-420	a	_	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
4-6	421-426	novel	_	_
4-7	427-437	continuous	_	_
4-8	438-448	functional	_	_
4-9	449-457	magnetic	_	_
4-10	458-467	resonance	_	_
4-11	468-475	imaging	_	_
4-12	476-485	technique	_	_
4-13	486-488	to	_	_
4-14	489-495	follow	_	_
4-15	496-499	the	_	_
4-16	500-516	minute‐to‐minute	_	_
4-17	517-526	evolution	_	_
4-18	527-529	of	_	_
4-19	530-535	brain	_	_
4-20	536-545	responses	_	_
4-21	545-546	,	_	_
4-22	547-552	which	_	_
4-23	553-562	correlate	_	_
4-24	563-567	with	_	_
4-25	568-571	the	_	_
4-26	572-578	waxing	_	_
4-27	579-582	and	_	_
4-28	583-589	waning	_	_
4-29	590-592	of	_	_
4-30	593-600	craving	_	_
4-31	600-601	.	_	_

5-1	602-607	Newly	_	_
5-2	608-618	detoxified	_	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
5-3	619-623	male	_	_
5-4	624-640	opioid‐dependent	_	_
5-5	641-649	patients	_	_
5-6	650-653	and	_	_
5-7	654-661	healthy	_	_
5-8	662-669	control	_	_
5-9	670-682	participants	_	_
5-10	683-691	attended	_	_
5-11	692-695	two	_	_
5-12	696-704	separate	_	_
5-13	704-705	,	_	_
5-14	706-721	counterbalanced	_	_
5-15	721-722	,	_	_
5-16	723-733	functional	_	_
5-17	734-742	magnetic	_	_
5-18	743-752	resonance	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire
5-19	753-760	imaging	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire
5-20	761-769	scanning	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire
5-21	770-778	sessions	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire
5-22	779-785	during	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	_
5-23	786-791	which	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	http://maven.renci.org/NeuroBridge/neurobridge#Thing
5-24	792-796	they	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	http://maven.renci.org/NeuroBridge/neurobridge#Thing
5-25	797-803	viewed	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	http://maven.renci.org/NeuroBridge/neurobridge#Thing
5-26	804-805	a	_	_
5-27	806-808	10	_	_
5-28	808-809	‐	_	_
5-29	809-815	minute	_	_
5-30	816-821	video	_	_
5-31	822-823	(	_	_
5-32	823-827	drug	_	_
5-33	828-831	cue	_	_
5-34	832-834	or	_	_
5-35	835-842	neutral	_	_
5-36	843-846	cue	_	_
5-37	846-847	)	_	_
5-38	848-856	followed	_	_
5-39	857-859	by	_	_
5-40	860-861	5	_	_
5-41	861-862	 	_	_
5-42	862-869	minutes	_	_
5-43	870-872	of	_	_
5-44	873-881	fixation	_	_
5-45	881-882	.	_	_

6-1	883-895	Participants	_	_
6-2	896-901	rated	_	_
6-3	902-905	the	_	_
6-4	906-915	intensity	_	_
6-5	916-918	of	_	_
6-6	919-924	their	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	_
6-7	925-932	craving	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
6-8	933-943	throughout	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
6-9	944-948	each	_	_
6-10	949-956	session	_	_
6-11	956-957	.	_	_

7-1	958-960	We	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
7-2	961-973	hypothesized	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
7-3	974-978	that	_	_
7-4	979-990	subcortical	_	_
7-5	990-991	/	_	_
7-6	991-998	ventral	_	_
7-7	999-1009	prefrontal	_	_
7-8	1010-1016	cortex	_	_
7-9	1017-1018	(	_	_
7-10	1018-1021	PFC	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	_
7-11	1021-1022	)	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	_
7-12	1023-1030	regions	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	_
7-13	1031-1034	and	_	_
7-14	1035-1041	dorsal	_	_
7-15	1042-1045	PFC	_	_
7-16	1046-1053	regions	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
7-17	1054-1059	would	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
7-18	1060-1064	show	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
7-19	1065-1074	different	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
7-20	1075-1087	associations	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
7-21	1088-1092	with	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
7-22	1093-1100	craving	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
7-23	1101-1111	reflecting	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
7-24	1112-1117	their	_	_
7-25	1118-1126	putative	_	_
7-26	1127-1132	roles	_	_
7-27	1133-1135	in	_	_
7-28	1136-1146	appetitive	_	_
7-29	1147-1157	processing	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
7-30	1158-1164	versus	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	_
7-31	1165-1174	cognitive	_	_
7-32	1175-1182	control	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	_
7-33	1182-1183	.	_	_

8-1	1184-1192	Compared	_	_
8-2	1193-1197	with	_	_
8-3	1198-1206	controls	_	_
8-4	1206-1207	,	_	_
8-5	1208-1212	drug	_	_
8-6	1213-1216	cue	_	_
8-7	1217-1218	(	_	_
8-8	1218-1223	minus	_	_
8-9	1224-1231	neutral	_	_
8-10	1232-1235	cue	_	_
8-11	1235-1236	)	_	_
8-12	1237-1242	video	_	_
8-13	1243-1252	recruited	_	_
8-14	1253-1256	the	_	_
8-15	1257-1261	left	_	_
8-16	1262-1270	amygdala	_	_
8-17	1271-1274	and	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
8-18	1275-1278	was	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	_
8-19	1279-1289	temporally	_	_
8-20	1290-1300	correlated	_	_
8-21	1301-1305	with	_	_
8-22	1306-1313	craving	_	_
8-23	1313-1314	.	_	_

9-1	1315-1317	In	_	_
9-2	1318-1326	contrast	_	_
9-3	1326-1327	,	_	_
9-4	1328-1334	dorsal	_	_
9-5	1335-1343	anterior	_	_
9-6	1344-1353	cingulate	_	_
9-7	1354-1382	blood‐oxygen‐level‐dependent	_	_
9-8	1383-1389	signal	_	_
9-9	1390-1394	time	_	_
9-10	1395-1401	course	_	_
9-11	1402-1405	was	_	_
9-12	1406-1412	higher	_	_
9-13	1413-1417	than	_	_
9-14	1418-1426	controls	_	_
9-15	1427-1431	only	_	_
9-16	1432-1438	during	_	_
9-17	1439-1440	a	_	_
9-18	1441-1447	period	_	_
9-19	1448-1453	after	_	_
9-20	1454-1457	cue	_	_
9-21	1458-1466	exposure	_	_
9-22	1467-1471	when	_	_
9-23	1472-1479	craving	_	_
9-24	1480-1486	levels	_	_
9-25	1487-1491	were	_	_
9-26	1492-1501	declining	_	_
9-27	1501-1502	.	_	_

10-1	1503-1510	Against	_	_
10-2	1511-1523	expectations	_	_
10-3	1523-1524	,	_	_
10-4	1525-1532	neither	_	_
10-5	1533-1536	the	_	_
10-6	1537-1544	ventral	_	_
10-7	1545-1553	striatum	_	_
10-8	1554-1557	nor	_	_
10-9	1558-1565	ventral	_	_
10-10	1566-1569	PFC	_	_
10-11	1570-1573	was	_	_
10-12	1574-1587	significantly	_	_
10-13	1588-1597	recruited	_	_
10-14	1598-1600	by	_	_
10-15	1601-1605	drug	_	_
10-16	1606-1609	cue	_	_
10-17	1610-1618	exposure	_	_
10-18	1618-1619	.	_	_

11-1	1620-1628	Findings	_	_
11-2	1629-1636	suggest	_	_
11-3	1637-1641	that	_	_
11-4	1642-1645	the	_	_
11-5	1646-1654	amygdala	_	_
11-6	1655-1658	has	_	_
11-7	1659-1660	a	_	_
11-8	1661-1668	central	_	_
11-9	1669-1673	role	_	_
11-10	1674-1676	in	_	_
11-11	1677-1684	craving	_	_
11-12	1684-1685	,	_	_
11-13	1686-1693	whereas	_	_
11-14	1694-1697	the	_	_
11-15	1698-1704	dorsal	_	_
11-16	1705-1713	anterior	_	_
11-17	1714-1723	cingulate	_	_
11-18	1724-1727	may	_	_
11-19	1728-1735	control	_	_
11-20	1736-1743	craving	_	_
11-21	1744-1746	in	_	_
11-22	1747-1764	treatment‐seeking	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	_
11-23	1765-1773	patients	_	_
11-24	1773-1774	.	_	_

12-1	1775-1779	Time	_	_
12-2	1780-1786	course	_	_
12-3	1787-1795	analysis	_	_
12-4	1796-1803	yielded	_	_
12-5	1804-1807	new	_	_
12-6	1808-1816	insights	_	_
12-7	1817-1821	into	_	_
12-8	1822-1825	the	_	_
12-9	1826-1832	neural	_	_
12-10	1833-1843	substrates	_	_
12-11	1844-1846	of	_	_
12-12	1847-1854	craving	_	_
12-13	1855-1859	that	_	_
12-14	1860-1865	could	_	_
12-15	1866-1877	objectively	_	_
12-16	1878-1886	validate	_	_
12-17	1887-1898	development	_	_
12-18	1899-1901	of	_	_
12-19	1902-1915	psychological	_	_
12-20	1916-1919	and	_	_
12-21	1920-1935	pharmacological	_	_
12-22	1936-1946	approaches	_	_
12-23	1947-1949	to	_	_
12-24	1950-1959	sustained	_	_
12-25	1960-1970	abstinence	_	_
12-26	1970-1971	.	_	_





















33-1	6617-6624	Methods	_	_
33-2	6625-6628	and	_	_
33-3	6629-6638	Materials	_	_
33-4	6639-6651	Participants	_	_
33-5	6652-6668	Opioid‐dependent	_	_
33-6	6669-6680	individuals	_	_
33-7	6681-6682	(	_	_
33-8	6682-6683	n	_	_
33-9	6683-6684	 	_	_
33-10	6684-6685	=	_	_
33-11	6685-6686	 	_	_
33-12	6686-6688	18	_	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
33-13	6688-6689	)	_	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
33-14	6690-6694	This	_	_
33-15	6695-6700	study	_	_
33-16	6701-6704	was	_	_
33-17	6705-6713	approved	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	_
33-18	6714-6716	by	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	_
33-19	6717-6720	the	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
33-20	6721-6724	NHS	_	_
33-21	6725-6733	Research	_	_
33-22	6734-6740	Ethics	_	_
33-23	6741-6750	Committee	_	_
33-24	6750-6751	.	_	_

34-1	6752-6764	Participants	_	_
34-2	6765-6769	with	_	_
34-3	6770-6772	OD	_	_
34-4	6773-6777	were	_	_
34-5	6778-6787	recruited	_	_
34-6	6788-6792	from	_	_
34-7	6793-6794	a	_	_
34-8	6795-6806	residential	_	_
34-9	6807-6821	detoxification	_	_
34-10	6822-6826	unit	_	_
34-11	6827-6833	within	_	_
34-12	6834-6841	Greater	_	_
34-13	6842-6852	Manchester	_	_
34-14	6853-6854	(	_	_
34-15	6854-6857	see	_	_
34-16	6858-6863	Table	_	_
34-17	6863-6864	 	_	_
34-18	6864-6865	1	_	_
34-19	6866-6869	for	_	_
34-20	6870-6881	demographic	_	_
34-21	6882-6893	information	_	_
34-22	6893-6894	)	_	_
34-23	6894-6895	.	_	_

35-1	6896-6905	Treatment	_	_
35-2	6906-6914	involved	_	_
35-3	6915-6916	a	_	_
35-4	6917-6918	4	_	_
35-5	6918-6919	‐	_	_
35-6	6919-6923	week	_	_
35-7	6924-6935	residential	_	_
35-8	6936-6940	stay	_	_
35-9	6941-6945	with	_	_
35-10	6946-6947	a	_	_
35-11	6948-6950	10	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
35-12	6950-6951	‐	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
35-13	6951-6954	day	_	_
35-14	6955-6964	methadone	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
35-15	6965-6978	stabilization	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
35-16	6979-6982	and	_	_
35-17	6983-6992	reduction	_	_
35-18	6992-6993	,	_	_
35-19	6994-7002	followed	_	_
35-20	7003-7005	by	_	_
35-21	7006-7008	10	_	_
35-22	7008-7009	 	_	_
35-23	7009-7013	days	_	_
35-24	7014-7016	of	_	_
35-25	7017-7027	lofexidine	_	_
35-26	7028-7037	treatment	_	_
35-27	7037-7038	,	_	_
35-28	7039-7041	an	_	_
35-29	7042-7047	alpha	_	_
35-30	7047-7048	‐	_	_
35-31	7048-7049	2	_	_
35-32	7050-7060	adrenergic	_	_
35-33	7061-7069	receptor	_	_
35-34	7070-7077	agonist	_	_
35-35	7078-7082	used	_	_
35-36	7083-7085	to	_	_
35-37	7086-7091	treat	_	_
35-38	7092-7098	opioid	_	_
35-39	7099-7109	withdrawal	_	_
35-40	7110-7118	symptoms	_	_
35-41	7118-7119	.	_	_

36-1	7120-7132	Participants	_	_
36-2	7133-7137	took	_	_
36-3	7138-7142	part	_	_
36-4	7143-7145	in	_	_
36-5	7146-7149	the	_	_
36-6	7150-7155	study	_	_
36-7	7156-7162	during	_	_
36-8	7163-7166	the	_	_
36-9	7167-7171	last	_	_
36-10	7172-7176	week	_	_
36-11	7177-7179	of	_	_
36-12	7180-7185	their	_	_
36-13	7186-7197	residential	_	_
36-14	7198-7202	stay	_	_
36-15	7203-7207	when	_	_
36-16	7208-7212	they	_	_
36-17	7213-7217	were	_	_
36-18	7218-7224	opioid	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
36-19	7225-7229	free	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
36-20	7230-7231	(	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod	http://maven.renci.org/NeuroBridge/neurobridge#StudyMethod
36-21	7231-7240	confirmed	_	_
36-22	7241-7243	by	_	_
36-23	7244-7249	urine	_	_
36-24	7250-7254	drug	_	_
36-25	7255-7261	screen	_	_
36-26	7261-7262	)	_	_
36-27	7262-7263	.	_	_

37-1	7264-7274	Lofexidine	_	_
37-2	7275-7278	was	_	_
37-3	7279-7287	extended	_	_
37-4	7288-7290	at	_	_
37-5	7291-7294	low	_	_
37-6	7295-7300	doses	_	_
37-7	7301-7304	for	_	_
37-8	7305-7317	participants	_	_
37-9	7318-7323	still	_	_
37-10	7324-7336	experiencing	_	_
37-11	7337-7347	withdrawal	_	_
37-12	7348-7356	symptoms	_	_
37-13	7357-7363	during	_	_
37-14	7364-7368	this	_	_
37-15	7369-7374	final	_	_
37-16	7375-7379	week	_	_
37-17	7379-7380	,	_	_
37-18	7381-7384	and	_	_
37-19	7385-7389	some	_	_
37-20	7390-7393	ODs	_	_
37-21	7394-7398	were	_	_
37-22	7399-7408	receiving	_	_
37-23	7409-7414	other	_	_
37-24	7415-7427	psychoactive	_	_
37-25	7428-7439	medications	_	_
37-26	7440-7442	as	_	_
37-27	7443-7452	indicated	_	_
37-28	7453-7455	by	_	_
37-29	7456-7466	Supporting	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
37-30	7467-7478	Information	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
37-31	7479-7484	Table	_	_
37-32	7484-7485	 	_	_
37-33	7486-7488	S1	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
37-34	7489-7490	.	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus

38-1	7491-7494	The	_	_
38-2	7495-7497	OD	_	_
38-3	7498-7503	group	_	_
38-4	7504-7507	was	_	_
38-5	7508-7517	recruited	_	_
38-6	7518-7527	according	_	_
38-7	7528-7530	to	_	_
38-8	7531-7534	the	_	_
38-9	7535-7544	following	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorderStatus
38-10	7545-7554	inclusion	http://maven.renci.org/NeuroBridge/neurobridge#SubstanceDisorder	_
38-11	7555-7563	criteria	_	_
38-12	7563-7564	:	_	_
38-13	7565-7569	male	_	_
38-14	7569-7570	,	_	_
38-15	7571-7575	aged	_	_
38-16	7576-7578	18	_	_
38-17	7578-7579	–	_	_
38-18	7579-7581	55	_	_
38-19	7581-7582	;	_	_
38-20	7583-7590	current	_	_
38-21	7591-7594	DSM	_	_
38-22	7595-7597	IV	_	_
38-23	7598-7604	heroin	_	_
38-24	7605-7615	dependence	_	_
38-25	7616-7617	(	_	_
38-26	7617-7620	the	_	_
38-27	7621-7629	majority	_	_
38-28	7630-7632	of	_	_
38-29	7633-7641	patients	_	_
38-30	7642-7646	also	_	_
38-31	7647-7650	met	_	_
38-32	7651-7659	criteria	_	_
38-33	7660-7663	for	_	_
38-34	7664-7671	current	_	_
38-35	7672-7674	or	_	_
38-36	7675-7679	past	_	_
38-37	7680-7690	dependence	_	_
38-38	7691-7693	on	_	_
38-39	7694-7699	other	_	_
38-40	7700-7710	substances	_	_
38-41	7710-7711	;	_	_
38-42	7712-7717	Table	_	_
38-43	7717-7718	 	_	_
38-44	7718-7719	1	_	_
38-45	7719-7720	)	_	_
38-46	7720-7721	;	_	_
38-47	7722-7724	no	_	_
38-48	7725-7732	history	_	_
38-49	7733-7735	of	_	_
38-50	7736-7743	serious	_	_
38-51	7744-7755	psychiatric	_	_
38-52	7755-7756	,	_	_
38-53	7757-7769	neurological	_	_
38-54	7770-7772	or	_	_
38-55	7773-7781	physical	_	_
38-56	7782-7789	illness	_	_
38-57	7789-7790	;	_	_
38-58	7791-7793	no	_	_
38-59	7794-7811	contraindications	_	_
38-60	7812-7815	for	_	_
38-61	7816-7819	MRI	_	_
38-62	7819-7820	;	_	_
38-63	7821-7824	and	_	_
38-64	7825-7827	IQ	_	_
38-65	7828-7830	of	_	_
38-66	7831-7832	≥	_	_
38-67	7832-7834	85	_	_
38-68	7835-7836	[	_	_
38-69	7836-7846	determined	_	_
38-70	7847-7852	using	_	_
38-71	7853-7856	the	_	_
38-72	7857-7865	Wechsler	_	_
38-73	7866-7870	Test	_	_
38-74	7871-7873	of	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
38-75	7874-7879	Adult	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
38-76	7880-7887	Reading	_	_
38-77	7888-7889	(	_	_
38-78	7889-7897	Holdnack	_	_
38-79	7898-7902	2001	_	_
38-80	7902-7903	)	_	_
38-81	7903-7904	]	_	_
38-82	7904-7905	.	_	_

39-1	7906-7918	Participants	_	_
39-2	7919-7923	were	_	_
39-3	7924-7934	identified	_	_
39-4	7935-7938	and	_	_
39-5	7939-7949	approached	_	_
39-6	7950-7952	by	_	_
39-7	7953-7960	members	_	_
39-8	7961-7963	of	_	_
39-9	7964-7967	the	_	_
39-10	7968-7976	clinical	_	_
39-11	7977-7981	team	_	_
39-12	7982-7984	on	_	_
39-13	7985-7988	the	_	_
39-14	7989-7994	basis	_	_
39-15	7995-7997	of	_	_
39-16	7998-8006	detailed	_	_
39-17	8007-8015	physical	_	_
39-18	8016-8019	and	_	_
39-19	8020-8026	mental	_	_
39-20	8027-8033	health	_	_
39-21	8034-8045	assessments	_	_
39-22	8046-8048	on	_	_
39-23	8049-8058	admission	_	_
39-24	8059-8061	to	_	_
39-25	8062-8065	the	_	_
39-26	8066-8070	unit	_	_
39-27	8070-8071	.	_	_

40-1	8072-8075	All	_	_
40-2	8076-8088	participants	_	_
40-3	8089-8096	meeting	_	_
40-4	8097-8100	the	_	_
40-5	8101-8110	inclusion	_	_
40-6	8111-8119	criteria	_	_
40-7	8120-8124	were	_	_
40-8	8125-8135	approached	_	_
40-9	8136-8138	to	_	_
40-10	8139-8143	take	_	_
40-11	8144-8148	part	_	_
40-12	8149-8151	in	_	_
40-13	8152-8155	the	_	_
40-14	8156-8161	study	_	_
40-15	8161-8162	.	_	_

41-1	8163-8164	A	_	_
41-2	8165-8170	total	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	_
41-3	8171-8173	of	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	_
41-4	8174-8176	39	_	_
41-5	8177-8185	patients	_	_
41-6	8186-8190	were	_	_
41-7	8191-8199	enrolled	_	_
41-8	8200-8202	in	_	_
41-9	8203-8206	the	_	_
41-10	8207-8214	craving	_	_
41-11	8215-8220	study	_	_
41-12	8220-8221	;	_	_
41-13	8222-8229	however	_	_
41-14	8229-8230	,	_	_
41-15	8231-8233	19	_	_
41-16	8234-8238	were	_	_
41-17	8239-8249	discharged	_	_
41-18	8250-8254	from	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	_
41-19	8255-8258	the	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	_
41-20	8259-8263	unit	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	_
41-21	8264-8270	before	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	_
41-22	8271-8274	any	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	_
41-23	8275-8282	testing	_	_
41-24	8283-8288	could	_	_
41-25	8289-8293	take	_	_
41-26	8294-8299	place	_	_
41-27	8300-8301	(	_	_
41-28	8301-8307	mainly	_	_
41-29	8308-8322	self‐discharge	_	_
41-30	8323-8325	or	_	_
41-31	8326-8331	early	_	_
41-32	8332-8341	discharge	_	_
41-33	8342-8345	due	_	_
41-34	8346-8348	to	_	_
41-35	8349-8352	use	_	_
41-36	8353-8355	of	_	_
41-37	8356-8366	prohibited	_	_
41-38	8367-8377	substances	_	_
41-39	8377-8378	)	_	_
41-40	8378-8379	.	_	_

42-1	8380-8386	Twenty	_	_
42-2	8387-8395	patients	_	_
42-3	8396-8400	were	_	_
42-4	8401-8408	scanned	_	_
42-5	8409-8411	as	_	_
42-6	8412-8416	part	_	_
42-7	8417-8419	of	_	_
42-8	8420-8423	the	_	_
42-9	8424-8429	study	_	_
42-10	8429-8430	,	_	_
42-11	8431-8439	although	_	_
42-12	8440-8443	two	_	_
42-13	8444-8448	were	_	_
42-14	8449-8457	excluded	_	_
42-15	8458-8462	from	_	_
42-16	8463-8471	analysis	_	_
42-17	8472-8479	because	_	_
42-18	8480-8482	of	_	_
42-19	8483-8492	excessive	_	_
42-20	8493-8501	movement	_	_
42-21	8502-8503	(	_	_
42-22	8503-8506	see	_	_
42-23	8507-8520	Preprocessing	_	_
42-24	8521-8528	section	_	_
42-25	8529-8532	for	_	_
42-26	8533-8540	further	_	_
42-27	8541-8548	details	_	_
42-28	8548-8549	)	_	_
42-29	8549-8550	,	_	_
42-30	8551-8558	leaving	_	_
42-31	8559-8560	n	_	_
42-32	8560-8561	 	_	_
42-33	8561-8562	=	_	_
42-34	8562-8563	 	_	_
42-35	8563-8565	18	_	_
42-36	8566-8569	who	_	_
42-37	8570-8574	were	_	_
42-38	8575-8583	included	_	_
42-39	8584-8586	in	_	_
42-40	8587-8595	analysis	_	_
42-41	8595-8596	.	_	_

43-1	8597-8607	Handedness	_	_
43-2	8608-8611	was	_	_
43-3	8612-8620	assessed	_	_
43-4	8621-8625	with	_	_
43-5	8626-8629	the	_	_
43-6	8630-8639	Edinburgh	_	_
43-7	8640-8650	Handedness	_	_
43-8	8651-8660	Inventory	_	_
43-9	8661-8662	(	_	_
43-10	8662-8670	Oldfield	_	_
43-11	8671-8675	1971	_	_
43-12	8675-8676	)	_	_
43-13	8676-8677	.	_	_

44-1	8678-8689	Demographic	_	_
44-2	8690-8693	and	_	_
44-3	8694-8702	clinical	_	_
44-4	8703-8714	information	_	_
44-5	8715-8717	of	_	_
44-6	8718-8720	OD	_	_
44-7	8721-8722	(	_	_
44-8	8722-8723	n	_	_
44-9	8723-8724	 	_	_
44-10	8724-8725	=	_	_
44-11	8725-8726	 	_	_
44-12	8726-8728	18	_	_
44-13	8728-8729	)	_	_
44-14	8730-8733	and	_	_
44-15	8734-8736	HC	_	_
44-16	8737-8738	(	_	_
44-17	8738-8739	n	_	_
44-18	8739-8740	 	_	_
44-19	8740-8741	=	_	_
44-20	8741-8742	 	_	_
44-21	8742-8744	20	_	_
44-22	8744-8745	)	_	_
44-23	8746-8752	groups	_	_
44-24	8753-8761	included	_	_
44-25	8762-8764	in	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	_
44-26	8765-8768	the	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	_
44-27	8769-8777	analysis	http://maven.renci.org/NeuroBridge/neurobridge#BarrattImpulsivenessQuestionnaire	_
44-28	8777-8778	.	_	_

45-1	8780-8782	OD	_	_
45-2	8783-8788	group	_	_
45-3	8789-8791	HC	_	_
45-4	8792-8797	group	_	_
45-5	8798-8805	p‐value	_	_
45-6	8808-8811	Age	_	_
45-7	8812-8816	34.8	_	_
45-8	8817-8818	(	_	_
45-9	8818-8821	6.3	_	_
45-10	8821-8822	)	_	_
45-11	8823-8827	31.6	_	_
45-12	8828-8829	(	_	_
45-13	8829-8832	7.2	_	_
45-14	8832-8833	)	_	_
45-15	8834-8838	0.15	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging	_
45-16	8841-8843	IQ	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
45-17	8844-8851	103.1.9	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging	_
45-18	8852-8853	(	_	_
45-19	8853-8856	7.7	_	_
45-20	8856-8857	)	_	_
45-21	8858-8863	114.1	_	_
45-22	8864-8865	(	_	http://maven.renci.org/NeuroBridge/neurobridge#WideRangeAchievementTest
45-23	8865-8868	4.7	_	http://maven.renci.org/NeuroBridge/neurobridge#WideRangeAchievementTest
45-24	8868-8869	)	_	_
45-25	8870-8871	<	_	http://maven.renci.org/NeuroBridge/neurobridge#DualEnergyXRayAbsorptiometry
45-26	8871-8875	0.05	_	http://maven.renci.org/NeuroBridge/neurobridge#DualEnergyXRayAbsorptiometry
45-27	8878-8883	Years	_	http://maven.renci.org/NeuroBridge/neurobridge#DualEnergyXRayAbsorptiometry
45-28	8884-8886	of	_	http://maven.renci.org/NeuroBridge/neurobridge#DualEnergyXRayAbsorptiometry
45-29	8887-8896	education	_	http://maven.renci.org/NeuroBridge/neurobridge#DualEnergyXRayAbsorptiometry
45-30	8897-8901	11.5	_	http://maven.renci.org/NeuroBridge/neurobridge#DualEnergyXRayAbsorptiometry
45-31	8902-8903	(	_	_
45-32	8903-8906	2.2	_	_
45-33	8906-8907	)	_	_
45-34	8908-8912	16.5	_	_
45-35	8913-8914	(	_	_
45-36	8914-8917	3.3	_	_
45-37	8917-8918	)	_	_
45-38	8919-8920	<	_	_
45-39	8920-8924	0.05	_	_
45-40	8927-8929	No	_	_
45-41	8929-8930	.	_	_
45-42	8931-8933	of	_	_
45-43	8934-8939	right	_	_
45-44	8940-8947	handers	_	_
45-45	8948-8950	16	_	_
45-46	8951-8952	(	_	_
45-47	8952-8954	89	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
45-48	8955-8962	percent	_	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
45-49	8962-8963	)	_	_
45-50	8964-8966	18	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
45-51	8967-8968	(	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
45-52	8968-8970	90	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
45-53	8971-8978	percent	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
45-54	8978-8979	)	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
45-55	8980-8984	0.91	_	_
45-56	8987-8989	No	_	_
45-57	8989-8990	.	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging
45-58	8991-8993	of	http://maven.renci.org/NeuroBridge/neurobridge#RestingStateImaging	_
45-59	8994-9001	smokers	_	_
45-60	9002-9003	(	_	_
45-61	9003-9011	nicotine	_	_
45-62	9011-9012	)	_	_
45-63	9013-9015	13	_	_
45-64	9016-9017	(	_	_
45-65	9017-9019	72	_	_
45-66	9020-9027	percent	_	_
45-67	9027-9028	)	_	_
45-68	9029-9030	9	_	_
45-69	9031-9032	(	_	_
45-70	9032-9034	45	_	_
45-71	9035-9042	percent	_	_
45-72	9042-9043	)	_	_
45-73	9044-9048	0.09	_	_
45-74	9051-9059	Clinical	_	_
45-75	9060-9069	Variables	_	_
45-76	9070-9073	for	_	_
45-77	9074-9076	OD	_	_
45-78	9077-9082	group	_	_
45-79	9088-9093	Years	_	_
45-80	9094-9096	of	_	_
45-81	9097-9103	opioid	_	_
45-82	9104-9114	dependence	_	_
45-83	9115-9119	12.8	_	_
45-84	9120-9121	(	_	_
45-85	9121-9124	7.7	_	_
45-86	9124-9125	)	_	_
45-87	9126-9127	—	_	_
45-88	9131-9138	Average	_	_
45-89	9139-9144	daily	_	_
45-90	9145-9151	opioid	_	_
45-91	9152-9155	use	_	_
45-92	9156-9157	(	_	_
45-93	9157-9158	g	_	_
45-94	9158-9159	)	_	_
45-95	9160-9163	0.7	_	_
45-96	9164-9165	(	_	_
45-97	9165-9168	0.6	_	_
45-98	9168-9169	)	_	_
45-99	9170-9171	—	_	_
45-100	9175-9178	Age	_	_
45-101	9179-9181	of	_	_
45-102	9182-9187	first	_	_
45-103	9188-9191	use	_	_
45-104	9192-9193	(	_	_
45-105	9193-9198	years	_	_
45-106	9198-9199	)	_	_
45-107	9200-9204	20.3	_	_
45-108	9205-9206	(	_	_
45-109	9206-9209	4.3	_	_
45-110	9209-9210	)	_	_
45-111	9215-9217	No	_	_
45-112	9217-9218	.	_	_
45-113	9219-9222	who	_	_
45-114	9223-9232	primarily	_	_
45-115	9233-9238	smoke	_	_
45-116	9238-9239	/	_	_
45-117	9239-9245	inject	_	_
45-118	9245-9246	/	_	_
45-119	9247-9249	or	_	_
45-120	9250-9253	use	_	_
45-121	9254-9258	both	_	_
45-122	9259-9266	methods	_	_
45-123	9267-9270	for	_	_
45-124	9271-9277	heroin	_	_
45-125	9278-9292	administration	_	_
45-126	9293-9294	5	_	_
45-127	9295-9296	(	_	_
45-128	9296-9298	28	_	_
45-129	9299-9306	percent	_	_
45-130	9306-9307	)	_	_
45-131	9307-9308	/	_	_
45-132	9308-9309	5	_	_
45-133	9310-9311	(	_	_
45-134	9311-9313	28	_	_
45-135	9314-9321	percent	_	_
45-136	9321-9322	)	_	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
45-137	9322-9323	/	_	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
45-138	9323-9324	8	_	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
45-139	9325-9326	(	_	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
45-140	9326-9328	44	_	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
45-141	9329-9336	percent	_	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
45-142	9336-9337	)	_	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
45-143	9338-9339	—	_	_
45-144	9343-9345	No	_	_
45-145	9345-9346	.	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	_
45-146	9347-9349	of	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
45-147	9350-9352	OD	_	_
45-148	9353-9358	group	_	_
45-149	9359-9363	with	_	_
45-150	9364-9371	current	_	_
45-151	9371-9372	/	_	_
45-152	9372-9376	past	_	_
45-153	9377-9384	history	_	_
45-154	9385-9387	of	_	_
45-155	9387-9388	:	_	_
45-156	9390-9391	—	_	_
45-157	9395-9402	Alcohol	_	_
45-158	9403-9413	dependence	_	_
45-159	9414-9415	7	_	_
45-160	9416-9417	(	_	_
45-161	9417-9419	39	_	_
45-162	9420-9427	percent	_	_
45-163	9427-9428	)	_	_
45-164	9429-9430	—	_	_
45-165	9434-9441	Cocaine	_	_
45-166	9442-9452	dependence	_	_
45-167	9453-9454	7	_	_
45-168	9455-9456	(	_	_
45-169	9456-9458	39	_	_
45-170	9459-9466	percent	_	_
45-171	9466-9467	)	_	_
45-172	9472-9483	Amphetamine	_	_
45-173	9484-9494	dependence	_	_
45-174	9495-9496	1	_	_
45-175	9497-9498	(	_	_
45-176	9498-9499	6	_	_
45-177	9500-9507	percent	_	_
45-178	9507-9508	)	_	_
45-179	9509-9510	—	_	_
45-180	9514-9528	Benzodiazepine	_	_
45-181	9529-9539	dependence	_	_
45-182	9540-9541	3	_	_
45-183	9542-9543	(	_	_
45-184	9543-9545	17	_	_
45-185	9546-9553	percent	_	_
45-186	9553-9554	)	_	_
45-187	9555-9556	—	_	_
45-188	9560-9566	Heroin	_	_
45-189	9567-9577	dependence	_	_
45-190	9578-9582	only	_	_
45-191	9583-9584	(	_	_
45-192	9584-9590	except	_	_
45-193	9591-9599	nicotine	_	_
45-194	9599-9600	)	_	_
45-195	9601-9602	6	_	_
45-196	9603-9604	(	_	_
45-197	9604-9606	33	_	_
45-198	9607-9614	percent	_	_
45-199	9614-9615	)	_	_
45-200	9616-9617	—	_	_
45-201	9622-9625	Age	_	_
45-202	9625-9626	,	_	_
45-203	9627-9629	IQ	_	_
45-204	9629-9630	,	_	_
45-205	9631-9636	years	_	_
45-206	9637-9639	of	_	_
45-207	9640-9649	education	_	_
45-208	9649-9650	,	_	_
45-209	9651-9656	years	_	_
45-210	9657-9659	of	_	_
45-211	9660-9670	dependence	_	_
45-212	9670-9671	,	_	_
45-213	9672-9679	average	_	_
45-214	9680-9685	daily	_	_
45-215	9686-9692	amount	_	_
45-216	9693-9697	used	_	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
45-217	9698-9701	and	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
45-218	9702-9705	age	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging	http://maven.renci.org/NeuroBridge/neurobridge#StructuralImaging
45-219	9706-9708	of	_	_
45-220	9709-9714	first	_	_
45-221	9715-9718	use	_	_
45-222	9719-9728	expressed	_	_
45-223	9729-9731	as	_	_
45-224	9732-9736	mean	_	_
45-225	9737-9740	and	_	_
45-226	9741-9749	standard	_	_
45-227	9750-9759	deviation	_	_
45-228	9760-9761	(	_	_
45-229	9761-9763	in	_	_
45-230	9764-9772	brackets	_	_
45-231	9772-9773	)	_	_
45-232	9773-9774	.	_	_

46-1	9775-9778	All	_	_
46-2	9779-9784	other	_	_
46-3	9785-9794	variables	_	_
46-4	9795-9804	expressed	_	_
46-5	9805-9807	as	_	_
46-6	9808-9817	frequency	_	_
46-7	9818-9821	and	_	_
46-8	9822-9832	proportion	_	_
46-9	9833-9835	of	_	_
46-10	9836-9841	group	_	_
46-11	9842-9843	(	_	_
46-12	9843-9845	in	_	_
46-13	9846-9854	brackets	_	_
46-14	9854-9855	)	_	_
46-15	9855-9856	.	_	_

47-1	9857-9865	P‐values	_	_
47-2	9866-9871	taken	_	_
47-3	9872-9876	from	_	_
47-4	9877-9888	independent	_	_
47-5	9889-9896	t‐tests	_	_
47-6	9897-9900	for	_	_
47-7	9901-9911	continuous	_	_
47-8	9912-9916	data	_	_
47-9	9917-9920	and	_	_
47-10	9921-9932	chi‐squared	_	_
47-11	9933-9938	tests	_	_
47-12	9939-9942	for	_	_
47-13	9943-9952	frequency	_	_
47-14	9953-9957	data	_	_
47-15	9957-9958	.	_	_

48-1	9959-9966	Healthy	_	_
48-2	9967-9975	controls	_	_
48-3	9976-9977	(	_	_
48-4	9977-9978	n	_	_
48-5	9978-9979	 	_	_
48-6	9979-9980	=	_	_
48-7	9980-9981	 	_	_
48-8	9981-9983	20	_	_
48-9	9983-9984	)	_	_
48-10	9985-9992	Healthy	_	_
48-11	9993-10001	controls	_	_
48-12	10002-10003	(	_	_
48-13	10003-10006	HCs	_	_
48-14	10006-10007	)	_	_
48-15	10008-10012	were	_	_
48-16	10013-10022	recruited	_	_
48-17	10023-10026	who	_	_
48-18	10027-10031	were	_	_
48-19	10032-10040	familiar	_	_
48-20	10041-10045	with	_	_
48-21	10046-10053	graphic	_	_
48-22	10054-10060	scenes	_	_
48-23	10061-10063	of	_	_
48-24	10064-10068	drug	_	http://maven.renci.org/NeuroBridge/neurobridge#Cholesterol
48-25	10069-10072	use	_	http://maven.renci.org/NeuroBridge/neurobridge#Cholesterol
48-26	10073-10080	because	_	http://maven.renci.org/NeuroBridge/neurobridge#Cholesterol
48-27	10081-10083	of	_	http://maven.renci.org/NeuroBridge/neurobridge#Cholesterol
48-28	10084-10096	occupational	_	_
48-29	10097-10107	experience	_	_
48-30	10108-10109	(	_	_
48-31	10109-10112	e.g	_	_
48-32	10112-10113	.	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
48-33	10114-10118	drug	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
48-34	10119-10128	treatment	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
48-35	10129-10136	workers	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging	http://maven.renci.org/NeuroBridge/neurobridge#T1WeightedImaging
48-36	10137-10140	and	_	_
48-37	10141-10146	other	_	_
48-38	10147-10153	health	_	_
48-39	10154-10167	professionals	_	_
48-40	10167-10168	)	_	_
48-41	10168-10169	.	_	_

49-1	10170-10173	The	_	_
49-2	10174-10176	HC	_	_
49-3	10177-10182	group	_	_
49-4	10183-10186	met	_	_
49-5	10187-10190	the	_	_
49-6	10191-10195	same	_	_
49-7	10196-10205	inclusion	_	_
49-8	10206-10214	criteria	_	_
49-9	10215-10223	outlined	_	_
49-10	10224-10234	previously	_	_
49-11	10235-10238	and	_	_
49-12	10239-10251	additionally	_	_
49-13	10252-10255	had	_	_
49-14	10256-10258	no	_	_
49-15	10259-10266	current	_	_
49-16	10267-10269	or	_	_
49-17	10270-10274	past	_	_
49-18	10275-10282	history	_	_
49-19	10283-10285	of	_	_
49-20	10286-10290	drug	_	_
49-21	10291-10301	dependence	_	_
49-22	10302-10304	or	_	_
49-23	10305-10311	misuse	_	_
49-24	10312-10313	(	_	_
49-25	10313-10319	except	_	_
49-26	10320-10328	nicotine	_	_
49-27	10328-10329	)	_	_
49-28	10330-10333	and	_	_
49-29	10334-10337	had	_	_
49-30	10338-10343	never	_	_
49-31	10344-10348	used	_	_
49-32	10349-10355	heroin	_	_
49-33	10356-10358	in	_	_
49-34	10359-10364	their	_	_
49-35	10365-10373	lifetime	_	_
49-36	10373-10374	.	_	_

50-1	10375-10377	No	_	_
50-2	10378-10385	healthy	_	_
50-3	10386-10396	volunteers	_	_
50-4	10397-10401	were	_	_
50-5	10402-10411	receiving	_	_
50-6	10412-10424	psychoactive	_	_
50-7	10425-10436	medications	_	_
50-8	10436-10437	.	_	_

51-1	10438-10450	Participants	_	_
51-2	10451-10455	were	_	_
51-3	10456-10464	screened	_	_
51-4	10465-10469	with	_	_
51-5	10470-10473	the	_	_
51-6	10474-10478	Mini	_	_
51-7	10479-10492	International	_	_
51-8	10493-10509	Neuropsychiatric	_	_
51-9	10510-10519	Interview	_	_
51-10	10520-10521	(	_	_
51-11	10521-10528	Sheehan	_	_
51-12	10529-10531	et	_	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
51-13	10532-10534	al	_	_
51-14	10534-10535	.	_	_
51-15	10536-10540	1998	_	_
51-16	10540-10541	)	_	_
51-17	10541-10542	,	_	_
51-18	10543-10551	Wechsler	_	_
51-19	10552-10556	Test	_	_
51-20	10557-10559	of	_	_
51-21	10560-10565	Adult	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging
51-22	10566-10573	Reading	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalImagingProtocol	_
51-23	10574-10577	and	_	_
51-24	10578-10587	Edinburgh	_	_
51-25	10588-10598	Handedness	_	_
51-26	10599-10608	Inventory	_	_
51-27	10608-10609	.	_	_

52-1	10610-10613	All	_	_
52-2	10614-10626	participants	_	_
52-3	10627-10635	provided	_	_
52-4	10636-10643	written	_	_
52-5	10644-10651	consent	_	_
52-6	10652-10655	and	_	_
52-7	10656-10660	were	_	_
52-8	10661-10665	paid	_	_
52-9	10666-10669	for	_	_
52-10	10670-10675	their	_	_
52-11	10676-10689	participation	_	_
52-12	10690-10694	with	_	_
52-13	10695-10703	vouchers	_	_
52-14	10703-10704	.	_	_

53-1	10705-10715	Procedures	_	_
53-2	10716-10728	Participants	_	_
53-3	10729-10737	attended	_	_
53-4	10738-10741	two	_	_
53-5	10742-10750	separate	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	_
53-6	10750-10751	,	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	_
53-7	10752-10767	counterbalanced	_	_
53-8	10768-10776	sessions	_	_
53-9	10776-10777	.	_	_

54-1	10778-10786	Patients	_	_
54-2	10787-10791	were	_	_
54-3	10792-10799	scanned	_	_
54-4	10800-10802	in	_	_
54-5	10803-10806	the	_	_
54-6	10807-10811	last	_	_
54-7	10812-10816	week	_	_
54-8	10817-10819	of	_	_
54-9	10820-10825	their	_	_
54-10	10826-10837	residential	_	_
54-11	10838-10842	stay	_	_
54-12	10843-10847	when	_	_
54-13	10848-10852	they	_	_
54-14	10853-10857	were	_	_
54-15	10858-10864	opioid	_	_
54-16	10865-10869	free	_	_
54-17	10869-10870	.	_	_

55-1	10871-10873	On	_	_
55-2	10874-10878	each	_	_
55-3	10879-10887	occasion	_	_
55-4	10887-10888	,	_	_
55-5	10889-10901	participants	_	_
55-6	10902-10911	underwent	_	_
55-7	10912-10916	fMRI	_	_
55-8	10916-10917	,	_	_
55-9	10918-10922	once	_	_
55-10	10923-10929	whilst	_	_
55-11	10930-10937	viewing	_	_
55-12	10938-10939	a	_	_
55-13	10940-10942	10	_	_
55-14	10942-10943	‐	_	_
55-15	10943-10949	minute	_	_
55-16	10950-10956	heroin	_	_
55-17	10957-10962	video	_	_
55-18	10963-10964	(	_	_
55-19	10964-10968	drug	_	_
55-20	10969-10972	cue	_	_
55-21	10973-10980	session	_	_
55-22	10980-10981	)	_	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
55-23	10982-10985	and	_	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
55-24	10986-10990	once	_	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
55-25	10991-10997	whilst	_	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
55-26	10998-11005	viewing	_	http://maven.renci.org/NeuroBridge/neurobridge#MolecularImaging
55-27	11006-11007	a	_	_
55-28	11008-11010	10	_	_
55-29	11010-11011	‐	_	_
55-30	11011-11017	minute	_	_
55-31	11018-11023	video	_	_
55-32	11024-11034	containing	_	_
55-33	11035-11041	scenes	_	_
55-34	11042-11049	matched	_	_
55-35	11050-11053	for	_	_
55-36	11054-11060	visual	_	_
55-37	11061-11071	complexity	_	_
55-38	11072-11075	but	_	_
55-39	11076-11083	lacking	_	_
55-40	11084-11095	emotionally	_	_
55-41	11096-11104	arousing	_	_
55-42	11105-11112	content	_	_
55-43	11113-11114	(	_	_
55-44	11114-11121	neutral	_	_
55-45	11122-11129	session	_	_
55-46	11129-11130	)	_	_
55-47	11130-11131	.	_	_

56-1	11132-11138	Videos	_	_
56-2	11139-11143	were	_	_
56-3	11144-11152	preceded	_	_
56-4	11153-11156	and	_	_
56-5	11157-11165	followed	_	_
56-6	11166-11168	by	_	_
56-7	11169-11170	5	_	_
56-8	11170-11171	 	_	_
56-9	11171-11178	minutes	_	_
56-10	11179-11181	of	_	_
56-11	11182-11190	fixation	_	_
56-12	11191-11192	(	_	_
56-13	11192-11195	Fig	_	_
56-14	11195-11196	.	_	_
56-15	11196-11197	 	_	_
56-16	11197-11198	1	_	_
56-17	11198-11199	)	_	_
56-18	11199-11200	.	_	_

57-1	11201-11207	Images	_	_
57-2	11208-11212	were	_	_
57-3	11213-11222	presented	_	_
57-4	11223-11228	using	_	_
57-5	11229-11236	e‐prime	_	_
57-6	11237-11238	(	_	_
57-7	11238-11248	Psychology	_	_
57-8	11249-11257	Software	_	_
57-9	11258-11263	Tools	_	_
57-10	11263-11264	,	_	_
57-11	11265-11268	Inc	_	_
57-12	11268-11269	,	_	_
57-13	11270-11280	Sharpsburg	_	_
57-14	11280-11281	,	_	_
57-15	11282-11285	USA	_	_
57-16	11285-11286	)	_	_
57-17	11287-11288	(	_	_
57-18	11288-11295	version	_	_
57-19	11296-11299	2.0	_	_
57-20	11299-11300	)	_	_
57-21	11300-11301	.	_	_

58-1	11302-11309	Diagram	_	_
58-2	11310-11322	illustrating	_	_
58-3	11323-11324	1	_	_
58-4	11324-11325	‐	_	_
58-5	11325-11331	minute	_	_
58-6	11332-11341	time‐bins	_	_
58-7	11342-11345	for	_	_
58-8	11346-11349	the	_	_
58-9	11350-11354	drug	_	_
58-10	11355-11358	cue	_	_
58-11	11359-11362	and	_	_
58-12	11363-11370	neutral	_	_
58-13	11371-11379	sessions	_	_
58-14	11379-11380	.	_	_

59-1	11381-11384	The	_	_
59-2	11385-11388	480	_	_
59-3	11389-11394	scans	_	_
59-4	11395-11399	were	_	_
59-5	11400-11407	divided	_	_
59-6	11408-11412	into	_	_
59-7	11413-11414	1	_	_
59-8	11414-11415	 	_	_
59-9	11415-11421	minute	_	_
59-10	11422-11431	time‐bins	_	_
59-11	11431-11432	.	_	_

60-1	11433-11435	T0	_	_
60-2	11436-11439	was	_	_
60-3	11440-11443	the	_	_
60-4	11444-11447	5th	_	_
60-5	11448-11454	minute	_	_
60-6	11455-11457	of	_	_
60-7	11458-11461	the	_	_
60-8	11462-11471	pre‐video	_	_
60-9	11472-11480	baseline	_	_
60-10	11480-11481	,	_	_
60-11	11482-11484	T1	_	_
60-12	11484-11485	–	_	_
60-13	11485-11488	T10	_	_
60-14	11489-11493	were	_	_
60-15	11494-11497	the	_	_
60-16	11498-11507	time‐bins	_	_
60-17	11508-11516	acquired	_	_
60-18	11517-11523	during	_	_
60-19	11524-11527	the	_	_
60-20	11528-11533	video	_	_
60-21	11534-11537	and	_	_
60-22	11538-11541	T11	_	_
60-23	11541-11542	‐	_	_
60-24	11542-11545	T15	_	_
60-25	11546-11550	were	_	_
60-26	11551-11554	the	_	_
60-27	11555-11565	post‐video	_	_
60-28	11566-11575	time‐bins	_	_
60-29	11575-11576	.	_	_

61-1	11577-11580	The	_	_
61-2	11581-11587	arrows	_	_
61-3	11588-11596	indicate	_	_
61-4	11597-11600	the	_	_
61-5	11601-11605	time	_	_
61-6	11606-11612	points	_	_
61-7	11613-11615	of	_	_
61-8	11616-11619	the	_	_
61-9	11620-11632	presentation	_	_
61-10	11633-11635	of	_	_
61-11	11636-11639	the	_	_
61-12	11640-11651	Likert‐like	_	_
61-13	11652-11662	subjective	_	_
61-14	11663-11669	rating	_	_
61-15	11670-11676	scales	_	_
61-16	11677-11685	Measures	_	_
61-17	11686-11698	Participants	_	_
61-18	11699-11703	were	_	_
61-19	11704-11713	presented	_	_
61-20	11714-11718	with	_	_
61-21	11719-11730	Likert‐like	_	_
61-22	11731-11741	subjective	_	_
61-23	11742-11748	rating	_	_
61-24	11749-11755	scales	_	_
61-25	11756-11766	throughout	_	_
61-26	11767-11770	the	_	_
61-27	11771-11779	scanning	_	_
61-28	11780-11787	session	_	_
61-29	11787-11788	.	_	_

62-1	11789-11801	Participants	_	_
62-2	11802-11806	were	_	_
62-3	11807-11815	prompted	_	_
62-4	11816-11818	to	_	_
62-5	11819-11826	respond	_	_
62-6	11827-11829	by	_	_
62-7	11830-11831	a	_	_
62-8	11832-11838	screen	_	_
62-9	11839-11849	displaying	_	_
62-10	11850-11853	the	_	_
62-11	11854-11863	following	_	_
62-12	11864-11868	text	_	_
62-13	11869-11870	‘	_	_
62-14	11870-11872	do	_	_
62-15	11873-11876	you	_	_
62-16	11877-11881	feel	_	_
62-17	11882-11885	you	_	_
62-18	11886-11889	are	_	_
62-19	11890-11891	…	_	_
62-20	11891-11892	’	_	_
62-21	11892-11893	,	_	_
62-22	11894-11899	which	_	_
62-23	11900-11903	was	_	_
62-24	11904-11913	presented	_	_
62-25	11914-11917	for	_	_
62-26	11918-11919	3	_	_
62-27	11919-11920	 	_	_
62-28	11920-11927	seconds	_	_
62-29	11928-11934	before	_	_
62-30	11935-11941	slides	_	_
62-31	11942-11949	stating	_	_
62-32	11950-11951	‘	_	_
62-33	11951-11958	Craving	_	_
62-34	11958-11959	?	_	_
62-35	11959-11960	’	_	_

63-1	11960-11961	,	_	_
63-2	11962-11963	‘	_	_
63-3	11963-11974	Withdrawing	_	_
63-4	11974-11975	?	_	_
63-5	11975-11976	’	_	_

64-1	11976-11977	,	_	_
64-2	11978-11979	‘	_	_
64-3	11979-11986	Anxious	_	_
64-4	11986-11987	?	_	_
64-5	11987-11988	’	_	_

65-1	11989-11991	or	_	_
65-2	11992-11993	‘	_	_
65-3	11993-11997	High	_	_
65-4	11997-11998	?	_	_
65-5	11998-11999	’	_	_

66-1	11999-12000	,	_	_
66-2	12001-12005	were	_	_
66-3	12006-12015	presented	_	_
66-4	12016-12019	for	_	_
66-5	12020-12021	4	_	_
66-6	12021-12022	 	_	_
66-7	12022-12029	seconds	_	_
66-8	12030-12035	along	_	_
66-9	12036-12040	with	_	_
66-10	12041-12044	the	_	_
66-11	12045-12054	following	_	_
66-12	12055-12060	scale	_	_
66-13	12060-12061	:	_	_
66-14	12062-12063	1	_	_
66-15	12064-12065	(	_	_
66-16	12065-12068	not	_	_
66-17	12069-12072	all	_	_
66-18	12072-12073	)	_	_
66-19	12073-12074	,	_	_
66-20	12075-12076	2	_	_
66-21	12077-12078	(	_	_
66-22	12078-12086	slightly	_	_
66-23	12086-12087	)	_	_
66-24	12087-12088	,	_	_
66-25	12089-12090	3	_	_
66-26	12091-12092	(	_	_
66-27	12092-12102	moderately	_	_
66-28	12102-12103	)	_	_
66-29	12104-12107	and	_	_
66-30	12108-12109	4	_	_
66-31	12110-12111	(	_	_
66-32	12111-12120	extremely	_	_
66-33	12120-12121	)	_	_
66-34	12121-12122	.	_	_

67-1	12123-12135	Participants	_	_
67-2	12136-12145	responded	_	_
67-3	12146-12149	via	_	_
67-4	12150-12151	a	_	_
67-5	12152-12158	button	_	_
67-6	12159-12162	box	_	_
67-7	12162-12163	.	_	_

68-1	12164-12167	The	_	_
68-2	12168-12174	scales	_	_
68-3	12175-12179	were	_	_
68-4	12180-12189	presented	_	_
68-5	12190-12192	at	_	_
68-6	12193-12194	3	_	_
68-7	12194-12195	‐	_	_
68-8	12195-12201	minute	_	_
68-9	12202-12211	intervals	_	_
68-10	12212-12214	in	_	_
68-11	12215-12219	each	_	_
68-12	12220-12227	session	_	_
68-13	12228-12229	(	_	_
68-14	12229-12232	Fig	_	_
68-15	12232-12233	.	_	_
68-16	12233-12234	 	_	_
68-17	12234-12235	1	_	_
68-18	12235-12236	)	_	_
68-19	12237-12248	Behavioural	_	_
68-20	12249-12253	data	_	_
68-21	12254-12259	Mixed	_	_
68-22	12260-12266	ANOVAs	_	_
68-23	12267-12271	were	_	_
68-24	12272-12279	carried	_	_
68-25	12280-12283	out	_	_
68-26	12284-12287	for	_	_
68-27	12288-12292	each	_	_
68-28	12293-12295	of	_	_
68-29	12296-12299	the	_	_
68-30	12300-12304	four	_	_
68-31	12305-12315	subjective	_	_
68-32	12316-12322	rating	_	_
68-33	12323-12329	scales	_	_
68-34	12330-12334	with	_	_
68-35	12335-12339	time	_	_
68-36	12340-12342	of	_	_
68-37	12343-12349	rating	_	_
68-38	12350-12351	(	_	_
68-39	12351-12354	six	_	_
68-40	12355-12361	levels	_	_
68-41	12362-12371	including	_	_
68-42	12372-12373	a	_	_
68-43	12374-12383	pre‐video	_	_
68-44	12384-12392	baseline	_	_
68-45	12393-12399	rating	_	_
68-46	12399-12400	,	_	_
68-47	12401-12406	three	_	_
68-48	12407-12413	during	_	_
68-49	12414-12417	the	_	_
68-50	12418-12423	video	_	_
68-51	12424-12427	and	_	_
68-52	12428-12431	two	_	_
68-53	12432-12442	post‐video	_	_
68-54	12443-12450	ratings	_	_
68-55	12450-12451	)	_	_
68-56	12452-12455	and	_	_
68-57	12456-12463	session	_	_
68-58	12464-12465	(	_	_
68-59	12465-12469	drug	_	_
68-60	12470-12473	cue	_	_
68-61	12473-12474	,	_	_
68-62	12475-12482	neutral	_	_
68-63	12482-12483	)	_	_
68-64	12484-12486	as	_	_
68-65	12487-12501	within‐subject	_	_
68-66	12502-12509	factors	_	_
68-67	12510-12513	and	_	_
68-68	12514-12519	group	_	_
68-69	12520-12521	(	_	_
68-70	12521-12523	HC	_	_
68-71	12523-12524	,	_	_
68-72	12525-12527	OD	_	_
68-73	12527-12528	)	_	_
68-74	12529-12531	as	_	_
68-75	12532-12535	the	_	_
68-76	12536-12551	between‐subject	_	_
68-77	12552-12558	factor	_	_
68-78	12558-12559	.	_	_

69-1	12560-12567	Session	_	_
69-2	12568-12573	order	_	_
69-3	12574-12577	was	_	_
69-4	12578-12586	included	_	_
69-5	12587-12589	as	_	_
69-6	12590-12591	a	_	_
69-7	12592-12601	covariate	_	_
69-8	12601-12602	.	_	_

70-1	12603-12606	The	_	_
70-2	12607-12616	pre‐video	_	_
70-3	12617-12623	rating	_	_
70-4	12624-12629	taken	_	_
70-5	12630-12636	during	_	_
70-6	12637-12640	the	_	_
70-7	12641-12645	last	_	_
70-8	12646-12652	minute	_	_
70-9	12653-12655	of	_	_
70-10	12656-12659	the	_	_
70-11	12660-12668	baseline	_	_
70-12	12669-12675	period	_	_
70-13	12676-12677	(	_	_
70-14	12677-12679	T0	_	_
70-15	12679-12680	)	_	_
70-16	12681-12684	was	_	_
70-17	12685-12689	used	_	_
70-18	12690-12692	as	_	_
70-19	12693-12696	the	_	_
70-20	12697-12706	pre‐video	_	_
70-21	12707-12715	baseline	_	_
70-22	12716-12722	rating	_	_
70-23	12722-12723	.	_	_

71-1	12724-12725	A	_	_
71-2	12726-12744	Greenhouse‐Geisser	_	_
71-3	12745-12755	correction	_	_
71-4	12756-12759	was	_	_
71-5	12760-12767	applied	_	_
71-6	12768-12772	when	_	_
71-7	12773-12783	Mauchley's	_	_
71-8	12784-12794	assumption	_	_
71-9	12795-12797	of	_	_
71-10	12798-12808	sphericity	_	_
71-11	12809-12812	was	_	_
71-12	12813-12821	violated	_	_
71-13	12821-12822	.	_	_

72-1	12823-12830	Ratings	_	_
72-2	12831-12835	from	_	_
72-3	12836-12839	one	_	_
72-4	12840-12842	HC	_	_
72-5	12843-12847	were	_	_
72-6	12848-12851	not	_	_
72-7	12852-12860	included	_	_
72-8	12861-12863	as	_	_
72-9	12864-12867	the	_	_
72-10	12868-12879	participant	_	_
72-11	12880-12885	could	_	_
72-12	12886-12889	not	_	_
72-13	12890-12893	see	_	_
72-14	12894-12897	the	_	_
72-15	12898-12904	rating	_	_
72-16	12905-12911	scales	_	_
72-17	12911-12912	.	_	_

73-1	12913-12921	Scanning	_	_
73-2	12922-12925	and	_	_
73-3	12926-12934	analysis	_	_
73-4	12935-12940	Whole	_	_
73-5	12941-12946	brain	_	_
73-6	12947-12949	T2	_	_
73-7	12949-12950	*	_	_
73-8	12951-12959	weighted	_	_
73-9	12960-12966	images	_	_
73-10	12967-12971	were	_	_
73-11	12972-12980	acquired	_	_
73-12	12981-12983	on	_	_
73-13	12984-12985	a	_	_
73-14	12986-12987	3	_	_
73-15	12988-12993	Tesla	_	_
73-16	12994-13001	Philips	_	_
73-17	13002-13009	Achieva	_	_
73-18	13010-13017	scanner	_	_
73-19	13018-13022	with	_	_
73-20	13023-13029	single	_	_
73-21	13030-13034	shot	_	_
73-22	13034-13035	,	_	_
73-23	13036-13047	multi‐slice	_	_
73-24	13048-13052	echo	_	_
73-25	13053-13059	planar	_	_
73-26	13060-13061	(	_	_
73-27	13061-13064	EPI	_	_
73-28	13064-13065	)	_	_
73-29	13066-13071	pulse	_	_
73-30	13072-13080	sequence	_	_
73-31	13080-13081	.	_	_

74-1	13082-13086	Each	_	_
74-2	13087-13093	volume	_	_
74-3	13094-13103	comprised	_	_
74-4	13104-13106	34	_	_
74-5	13107-13117	contiguous	_	_
74-6	13118-13123	axial	_	_
74-7	13124-13130	slices	_	_
74-8	13131-13132	(	_	_
74-9	13132-13134	TR	_	_
74-10	13134-13135	 	_	_
74-11	13135-13136	=	_	_
74-12	13136-13137	 	_	_
74-13	13137-13140	2.5	_	_
74-14	13140-13141	 	_	_
74-15	13141-13142	s	_	_
74-16	13142-13143	,	_	_
74-17	13144-13146	TE	_	_
74-18	13146-13147	 	_	_
74-19	13147-13148	=	_	_
74-20	13148-13149	 	_	_
74-21	13149-13151	35	_	_
74-22	13151-13152	 	_	_
74-23	13152-13154	ms	_	_
74-24	13154-13155	,	_	_
74-25	13156-13158	96	_	_
74-26	13158-13159	 	_	_
74-27	13159-13160	×	_	_
74-28	13160-13161	 	_	_
74-29	13161-13163	96	_	_
74-30	13164-13170	matrix	_	_
74-31	13170-13171	,	_	_
74-32	13172-13180	in‐plane	_	_
74-33	13181-13186	voxel	_	_
74-34	13187-13191	size	_	_
74-35	13192-13195	3.0	_	_
74-36	13195-13196	 	_	_
74-37	13196-13198	mm	_	_
74-38	13198-13199	 	_	_
74-39	13199-13200	×	_	_
74-40	13200-13201	 	_	_
74-41	13201-13204	3.0	_	_
74-42	13204-13205	 	_	_
74-43	13205-13207	mm	_	_
74-44	13207-13208	,	_	_
74-45	13209-13214	slice	_	_
74-46	13215-13224	thickness	_	_
74-47	13225-13228	3.5	_	_
74-48	13228-13229	 	_	_
74-49	13229-13231	mm	_	_
74-50	13231-13232	)	_	_
74-51	13232-13233	.	_	_

75-1	13234-13235	A	_	_
75-2	13236-13251	high‐resolution	_	_
75-3	13252-13254	T1	_	_
75-4	13254-13255	‐	_	_
75-5	13255-13263	weighted	_	_
75-6	13264-13274	structural	_	_
75-7	13275-13280	image	_	_
75-8	13281-13284	was	_	_
75-9	13285-13289	also	_	_
75-10	13290-13298	acquired	_	_
75-11	13299-13302	for	_	_
75-12	13303-13307	each	_	_
75-13	13308-13319	participant	_	_
75-14	13320-13323	for	_	_
75-15	13324-13338	coregistration	_	_
75-16	13339-13345	during	_	_
75-17	13346-13359	preprocessing	_	_
75-18	13360-13363	and	_	_
75-19	13364-13366	to	_	_
75-20	13367-13374	exclude	_	_
75-21	13375-13378	any	_	_
75-22	13379-13389	structural	_	_
75-23	13390-13401	abnormality	_	_
75-24	13401-13402	.	_	_

76-1	13403-13416	Preprocessing	_	_
76-2	13417-13427	Functional	_	_
76-3	13428-13432	data	_	_
76-4	13433-13437	were	_	_
76-5	13438-13446	analysed	_	_
76-6	13447-13452	using	_	_
76-7	13453-13464	statistical	_	_
76-8	13465-13475	parametric	_	_
76-9	13476-13483	mapping	_	_
76-10	13484-13485	(	_	_
76-11	13485-13489	SPM8	_	_
76-12	13489-13490	;	_	_
76-13	13491-13494	The	_	_
76-14	13495-13503	Wellcome	_	_
76-15	13504-13514	Department	_	_
76-16	13515-13517	of	_	_
76-17	13518-13527	Cognitive	_	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
76-18	13528-13537	Neurology	_	_
76-19	13537-13538	,	_	_
76-20	13539-13545	London	_	_
76-21	13545-13546	,	_	_
76-22	13547-13549	UK	_	_
76-23	13549-13550	)	_	_
76-24	13551-13558	running	_	_
76-25	13559-13561	in	_	_
76-26	13562-13568	MATLAB	_	_
76-27	13569-13570	(	_	_
76-28	13570-13576	Matlab	_	_
76-29	13576-13577	,	_	_
76-30	13578-13584	R2012a	_	_
76-31	13584-13585	;	_	_
76-32	13586-13595	Mathworks	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
76-33	13595-13596	,	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
76-34	13597-13603	Natick	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse
76-35	13603-13604	,	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse
76-36	13605-13618	Massachusetts	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse
76-37	13618-13619	,	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse
76-38	13620-13625	U.S.A	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#NondependentAlcoholAbuse
76-39	13625-13626	.	_	_
76-40	13626-13627	)	_	_
76-41	13627-13628	.	_	_

77-1	13629-13639	Functional	_	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
77-2	13640-13646	images	_	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
77-3	13647-13651	were	_	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
77-4	13652-13661	realigned	_	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
77-5	13662-13665	and	_	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
77-6	13666-13678	coregistered	_	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
77-7	13679-13683	with	_	_
77-8	13684-13687	the	_	_
77-9	13688-13690	T1	_	_
77-10	13691-13701	structural	_	_
77-11	13702-13707	image	_	_
77-12	13708-13714	before	_	_
77-13	13715-13728	normalization	_	_
77-14	13729-13731	of	_	_
77-15	13732-13735	the	_	_
77-16	13736-13746	functional	_	_
77-17	13747-13753	images	_	_
77-18	13754-13758	into	_	_
77-19	13759-13767	standard	_	_
77-20	13768-13773	space	_	_
77-21	13774-13777	was	_	_
77-22	13778-13785	carried	_	_
77-23	13786-13789	out	_	_
77-24	13790-13795	using	_	_
77-25	13796-13799	the	_	_
77-26	13800-13807	unified	_	_
77-27	13808-13820	segmentation	_	_
77-28	13821-13829	approach	_	_
77-29	13830-13831	(	_	_
77-30	13831-13840	Ashburner	_	_
77-31	13841-13842	&	_	_
77-32	13843-13850	Friston	_	_
77-33	13851-13855	2005	_	_
77-34	13855-13856	)	_	_
77-35	13856-13857	.	_	_

78-1	13858-13868	Normalized	_	_
78-2	13869-13875	images	_	_
78-3	13876-13880	were	_	_
78-4	13881-13889	smoothed	_	_
78-5	13890-13895	using	_	_
78-6	13896-13898	an	_	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
78-7	13899-13900	8	_	_
78-8	13900-13901	‐	_	_
78-9	13901-13903	mm	_	_
78-10	13904-13912	Gaussian	_	_
78-11	13913-13919	kernel	_	_
78-12	13919-13920	.	_	_

79-1	13921-13924	The	_	_
79-2	13925-13933	smoothed	_	_
79-3	13934-13944	functional	_	_
79-4	13945-13951	images	_	_
79-5	13952-13954	of	_	_
79-6	13955-13958	the	_	_
79-7	13959-13971	participants	_	_
79-8	13972-13975	who	_	_
79-9	13976-13981	moved	_	_
79-10	13982-13986	more	_	_
79-11	13987-13991	than	_	_
79-12	13992-13993	1	_	_
79-13	13993-13994	 	_	_
79-14	13994-13999	voxel	_	_
79-15	14000-14004	were	_	_
79-16	14005-14013	repaired	_	_
79-17	14014-14016	by	_	_
79-18	14017-14019	an	_	_
79-19	14020-14033	interpolation	_	_
79-20	14034-14040	method	_	_
79-21	14041-14046	using	_	_
79-22	14047-14050	the	_	_
79-23	14051-14059	artefact	_	_
79-24	14060-14066	repair	_	_
79-25	14067-14074	toolbox	_	_
79-26	14075-14076	(	_	_
79-27	14076-14080	http	_	_
79-28	14080-14081	:	_	_
79-29	14081-14082	/	_	_
79-30	14082-14083	/	_	_
79-31	14083-14101	cibsr.stanford.edu	_	_
79-32	14101-14102	/	_	_
79-33	14102-14107	tools	_	_
79-34	14107-14108	/	_	_
79-35	14108-14117	ArtRepair	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
79-36	14117-14118	/	_	_
79-37	14118-14131	ArtRepair.htm	_	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
79-38	14131-14132	)	_	_
79-39	14132-14133	.	_	_

80-1	14134-14137	Two	_	_
80-2	14138-14141	ODs	_	_
80-3	14142-14146	with	_	_
80-4	14147-14156	excessive	_	_
80-5	14157-14165	movement	_	_
80-6	14166-14170	were	_	_
80-7	14171-14179	excluded	_	_
80-8	14180-14181	(	_	_
80-9	14181-14182	>	_	_
80-10	14182-14184	10	_	_
80-11	14185-14192	percent	_	_
80-12	14193-14200	volumes	_	_
80-13	14201-14208	needing	_	_
80-14	14209-14218	repairing	_	_
80-15	14218-14219	)	_	_
80-16	14219-14220	.	_	_

81-1	14221-14229	Eighteen	_	_
81-2	14230-14233	ODs	_	_
81-3	14234-14237	and	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
81-4	14238-14240	20	_	_
81-5	14241-14244	HCs	_	_
81-6	14245-14249	were	_	_
81-7	14250-14257	entered	_	_
81-8	14258-14262	into	_	_
81-9	14263-14273	subsequent	_	_
81-10	14274-14282	analyses	_	_
81-11	14282-14283	.	_	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia

82-1	14284-14295	First‐level	_	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
82-2	14296-14304	analysis	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#Schizophrenia
82-3	14305-14308	For	_	_
82-4	14309-14313	both	_	_
82-5	14314-14317	the	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
82-6	14318-14322	drug	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
82-7	14323-14326	cue	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
82-8	14327-14330	and	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
82-9	14331-14334	the	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#ControlSubject
82-10	14335-14342	neutral	_	_
82-11	14343-14350	session	_	_
82-12	14350-14351	,	_	_
82-13	14352-14356	data	_	_
82-14	14357-14361	were	_	_
82-15	14362-14370	acquired	_	_
82-16	14371-14383	continuously	_	_
82-17	14384-14387	for	_	_
82-18	14388-14390	20	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
82-19	14390-14391	 	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
82-20	14391-14398	minutes	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
82-21	14399-14400	(	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
82-22	14400-14401	5	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
82-23	14401-14402	 	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	_
82-24	14402-14409	minutes	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	_
82-25	14410-14416	before	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
82-26	14417-14420	the	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
82-27	14421-14426	start	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
82-28	14427-14429	of	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	http://maven.renci.org/NeuroBridge/neurobridge#MagneticResonanceImaging
82-29	14430-14434	each	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	_
82-30	14435-14440	video	_	_
82-31	14441-14443	to	_	_
82-32	14444-14449	allow	_	_
82-33	14450-14462	participants	_	_
82-34	14463-14465	to	_	_
82-35	14466-14477	acclimatize	_	_
82-36	14478-14480	to	_	_
82-37	14481-14484	the	_	_
82-38	14485-14492	scanner	_	_
82-39	14493-14504	environment	_	_
82-40	14504-14505	,	_	_
82-41	14506-14508	10	_	_
82-42	14508-14509	 	_	_
82-43	14509-14516	minutes	_	_
82-44	14517-14523	during	_	_
82-45	14524-14536	presentation	_	_
82-46	14537-14539	of	_	_
82-47	14540-14543	the	_	_
82-48	14544-14549	video	_	_
82-49	14550-14553	and	_	_
82-50	14554-14556	an	_	_
82-51	14557-14567	additional	_	_
82-52	14568-14569	5	_	_
82-53	14569-14570	 	_	_
82-54	14570-14577	minutes	_	_
82-55	14578-14583	after	_	_
82-56	14584-14587	the	_	_
82-57	14588-14591	end	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#DiseaseDiagnosis
82-58	14592-14594	of	_	http://maven.renci.org/NeuroBridge/neurobridge#DiseaseDiagnosis
82-59	14595-14598	the	_	_
82-60	14599-14604	video	_	_
82-61	14604-14605	)	_	_
82-62	14606-14607	(	_	_
82-63	14607-14610	Fig	_	_
82-64	14610-14611	.	_	_
82-65	14611-14612	 	_	_
82-66	14612-14613	1	_	_
82-67	14613-14614	)	_	_
82-68	14614-14615	.	_	_

83-1	14616-14619	The	_	_
83-2	14620-14629	resultant	_	_
83-3	14630-14633	480	_	_
83-4	14634-14642	acquired	_	_
83-5	14643-14648	scans	_	_
83-6	14649-14653	were	_	_
83-7	14654-14661	divided	_	_
83-8	14662-14666	into	_	_
83-9	14667-14668	1	_	_
83-10	14668-14669	‐	_	_
83-11	14669-14675	minute	_	_
83-12	14676-14685	time‐bins	_	_
83-13	14686-14687	(	_	_
83-14	14687-14689	20	_	_
83-15	14690-14699	time‐bins	_	_
83-16	14700-14702	in	_	_
83-17	14703-14708	total	_	_
83-18	14708-14709	)	_	_
83-19	14709-14710	.	_	_

84-1	14711-14714	The	_	_
84-2	14715-14718	5th	_	_
84-3	14719-14725	minute	_	_
84-4	14726-14728	of	_	_
84-5	14729-14732	the	_	_
84-6	14733-14742	pre‐video	_	_
84-7	14743-14751	baseline	_	_
84-8	14752-14755	was	_	_
84-9	14756-14763	treated	_	_
84-10	14764-14766	as	_	_
84-11	14767-14770	the	_	_
84-12	14771-14779	baseline	_	_
84-13	14780-14788	time‐bin	_	_
84-14	14789-14791	T0	_	_
84-15	14791-14792	,	_	_
84-16	14793-14797	with	_	_
84-17	14798-14802	each	_	_
84-18	14803-14813	subsequent	_	_
84-19	14814-14822	time‐bin	_	_
84-20	14823-14824	(	_	_
84-21	14824-14826	T1	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#DiseaseDiagnosis
84-22	14826-14827	–	_	http://maven.renci.org/NeuroBridge/neurobridge#DiseaseDiagnosis
84-23	14827-14829	15	_	_
84-24	14829-14830	)	_	_
84-25	14831-14839	compared	_	_
84-26	14840-14844	with	_	_
84-27	14845-14847	T0	_	_
84-28	14848-14853	using	_	_
84-29	14854-14864	regression	_	_
84-30	14865-14873	analysis	_	_
84-31	14874-14880	within	_	_
84-32	14881-14882	a	_	_
84-33	14883-14890	general	_	_
84-34	14891-14897	linear	_	_
84-35	14898-14903	model	_	_
84-36	14904-14913	framework	_	_
84-37	14913-14914	.	_	_

85-1	14915-14918	The	_	_
85-2	14919-14924	exact	_	_
85-3	14925-14930	shape	_	_
85-4	14931-14933	of	_	_
85-5	14934-14937	the	_	_
85-6	14938-14944	signal	_	_
85-7	14945-14947	of	_	_
85-8	14948-14956	interest	_	_
85-9	14957-14960	was	_	_
85-10	14961-14968	unknown	_	_
85-11	14968-14969	;	_	_
85-12	14970-14979	therefore	_	_
85-13	14979-14980	,	_	_
85-14	14981-14983	no	_	_
85-15	14984-14993	high‐pass	_	_
85-16	14994-15000	filter	_	_
85-17	15001-15004	was	_	_
85-18	15005-15009	used	_	_
85-19	15009-15010	.	_	_

86-1	15011-15014	The	_	_
86-2	15015-15022	neutral	_	_
86-3	15023-15030	session	_	_
86-4	15031-15039	averages	_	_
86-5	15040-15044	were	_	_
86-6	15045-15055	subtracted	_	_
86-7	15056-15060	from	_	_
86-8	15061-15064	the	_	_
86-9	15065-15069	time	_	_
86-10	15070-15080	equivalent	_	_
86-11	15081-15085	drug	_	_
86-12	15086-15089	cue	_	_
86-13	15090-15097	session	_	_
86-14	15098-15106	averages	_	_
86-15	15106-15107	,	_	_
86-16	15108-15117	resulting	_	_
86-17	15118-15120	in	_	_
86-18	15121-15122	‘	_	_
86-19	15122-15126	drug	_	_
86-20	15127-15130	cue	_	_
86-21	15131-15146	session–neutral	_	_
86-22	15147-15154	session	_	_
86-23	15154-15155	’	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#Thing
86-24	15156-15164	contrast	_	_
86-25	15165-15171	images	_	_
86-26	15171-15172	.	_	_

87-1	15173-15191	Region‐of‐interest	_	_
87-2	15192-15200	analysis	_	_
87-3	15201-15202	A	_	_
87-4	15203-15221	region‐of‐interest	_	_
87-5	15222-15223	(	_	_
87-6	15223-15226	ROI	_	_
87-7	15226-15227	)	_	_
87-8	15228-15236	approach	_	_
87-9	15237-15240	was	_	_
87-10	15241-15245	used	_	_
87-11	15246-15248	to	_	_
87-12	15249-15256	extract	_	_
87-13	15257-15261	time	_	_
87-14	15262-15268	course	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	_
87-15	15269-15276	signals	_	_
87-16	15277-15281	from	_	_
87-17	15282-15285	key	_	_
87-18	15286-15291	brain	_	_
87-19	15292-15299	regions	_	_
87-20	15300-15308	involved	_	_
87-21	15309-15311	in	_	_
87-22	15312-15316	drug	_	_
87-23	15317-15320	cue	_	_
87-24	15321-15331	reactivity	_	_
87-25	15332-15337	based	_	_
87-26	15338-15340	on	_	_
87-27	15341-15347	recent	_	_
87-28	15348-15361	meta‐analyses	_	_
87-29	15362-15363	(	_	_
87-30	15363-15368	Chase	_	_
87-31	15369-15371	et	_	_
87-32	15372-15374	al	_	_
87-33	15374-15375	.	_	_
87-34	15376-15380	2011	_	_
87-35	15380-15381	;	_	_
87-36	15382-15386	Kuhn	_	_
87-37	15387-15388	&	_	_
87-38	15389-15397	Gallinat	_	_
87-39	15398-15402	2011	_	_
87-40	15402-15403	)	_	_
87-41	15403-15404	.	_	_

88-1	15405-15410	These	_	_
88-2	15411-15419	composed	_	_
88-3	15420-15422	of	_	_
88-4	15423-15430	spheres	_	_
88-5	15431-15433	of	_	_
88-6	15434-15435	7	_	_
88-7	15435-15436	‐	_	_
88-8	15436-15438	mm	_	_
88-9	15439-15445	radius	_	_
88-10	15446-15453	centred	_	_
88-11	15454-15460	around	_	_
88-12	15461-15464	the	_	_
88-13	15465-15474	bilateral	_	_
88-14	15475-15482	ventral	_	_
88-15	15483-15491	striatum	_	_
88-16	15491-15492	,	_	_
88-17	15493-15501	amygdala	_	_
88-18	15502-15505	and	_	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
88-19	15506-15511	VmPFC	_	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
88-20	15511-15512	,	_	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
88-21	15513-15524	coordinates	_	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
88-22	15525-15529	from	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
88-23	15530-15535	Chase	_	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
88-24	15536-15538	et	_	_
88-25	15539-15541	al	_	_
88-26	15541-15542	.	_	_
88-27	15543-15544	(	_	_
88-28	15544-15548	2011	_	_
88-29	15548-15549	)	_	_
88-30	15549-15550	,	_	_
88-31	15551-15554	and	_	_
88-32	15555-15563	anterior	_	_
88-33	15564-15573	cingulate	_	_
88-34	15574-15580	cortex	_	_
88-35	15580-15581	,	_	_
88-36	15582-15593	coordinates	_	_
88-37	15594-15598	from	_	_
88-38	15599-15603	Kuhn	_	_
88-39	15604-15605	&	_	_
88-40	15606-15614	Gallinat	_	_
88-41	15615-15616	(	_	_
88-42	15616-15620	2011	_	_
88-43	15620-15621	)	_	_
88-44	15621-15622	,	_	_
88-45	15623-15625	as	_	_
88-46	15626-15635	displayed	_	_
88-47	15636-15638	in	_	_
88-48	15639-15642	Fig	_	_
88-49	15642-15643	.	_	_
88-50	15643-15644	 	_	_
88-51	15644-15645	3	_	_
88-52	15645-15646	.	_	_

89-1	15647-15651	Mean	_	_
89-2	15652-15656	drug	_	_
89-3	15657-15668	cue‐neutral	_	_
89-4	15669-15676	session	_	_
89-5	15677-15685	contrast	_	_
89-6	15686-15695	estimates	_	_
89-7	15696-15700	were	_	_
89-8	15701-15710	extracted	_	_
89-9	15711-15715	from	_	_
89-10	15716-15720	each	_	_
89-11	15721-15723	of	_	_
89-12	15724-15727	the	_	http://maven.renci.org/NeuroBridge/neurobridge#MajorDepressiveDisorder
89-13	15728-15731	six	_	_
89-14	15732-15736	ROIs	_	_
89-15	15737-15742	using	_	_
89-16	15743-15746	the	_	_
89-17	15747-15751	Easy	_	_
89-18	15752-15755	ROI	_	_
89-19	15756-15763	toolbox	_	_
89-20	15764-15775	implemented	_	_
89-21	15776-15778	in	_	_
89-22	15779-15782	SPM	_	_
89-23	15783-15784	(	_	_
89-24	15784-15788	http	_	_
89-25	15788-15789	:	_	_
89-26	15789-15790	/	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
89-27	15790-15791	/	_	_
89-28	15791-15809	www.sbirc.ed.ac.uk	_	_
89-29	15809-15810	/	_	_
89-30	15810-15813	LCL	_	_
89-31	15813-15814	/	_	_
89-32	15814-15820	LCL_M1	_	_
89-33	15820-15821	.	_	_
89-34	15821-15825	html	_	_
89-35	15825-15826	)	_	_
89-36	15827-15830	and	_	_
89-37	15831-15838	entered	_	_
89-38	15839-15843	into	_	_
89-39	15844-15849	mixed	_	_
89-40	15850-15856	ANOVAs	_	_
89-41	15857-15859	in	_	_
89-42	15860-15864	SPSS	_	_
89-43	15865-15866	(	_	_
89-44	15866-15873	version	_	_
89-45	15874-15876	20	_	_
89-46	15876-15877	)	_	_
89-47	15878-15880	to	_	_
89-48	15881-15892	investigate	_	_
89-49	15893-15900	effects	_	_
89-50	15901-15903	of	_	_
89-51	15904-15908	time	_	_
89-52	15909-15912	and	_	_
89-53	15913-15918	group	_	_
89-54	15919-15921	on	_	_
89-55	15922-15926	drug	_	_
89-56	15927-15938	cue‐neutral	_	_
89-57	15939-15946	session	_	_
89-58	15947-15951	BOLD	_	_
89-59	15952-15958	signal	_	_
89-60	15958-15959	.	_	_

90-1	15960-15974	Investigations	_	_
90-2	15975-15979	were	_	_
90-3	15980-15987	carried	_	_
90-4	15988-15991	out	_	_
90-5	15992-15995	for	_	_
90-6	15996-15999	the	_	_
90-7	16000-16005	whole	_	_
90-8	16006-16013	session	_	_
90-9	16014-16015	(	_	_
90-10	16015-16017	T0	_	_
90-11	16018-16020	to	_	_
90-12	16021-16024	T15	_	_
90-13	16024-16025	)	_	_
90-14	16026-16029	and	_	_
90-15	16030-16033	for	_	_
90-16	16034-16037	the	_	_
90-17	16038-16043	video	_	_
90-18	16044-16053	time‐bins	_	_
90-19	16054-16055	(	_	_
90-20	16055-16057	T1	_	_
90-21	16057-16058	–	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale
90-22	16058-16061	T10	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale
90-23	16061-16062	)	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale
90-24	16063-16066	and	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale
90-25	16067-16077	post‐video	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale
90-26	16078-16087	time‐bins	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale	http://maven.renci.org/NeuroBridge/neurobridge#Montgomery–AsbergDepressionRatingScale
90-27	16088-16098	separately	_	_
90-28	16099-16100	(	_	_
90-29	16100-16103	T11	_	_
90-30	16104-16106	to	_	_
90-31	16107-16110	T15	_	_
90-32	16110-16111	)	_	_
90-33	16112-16116	with	_	_
90-34	16117-16124	session	_	_
90-35	16125-16130	order	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
90-36	16131-16139	included	_	_
90-37	16140-16142	as	_	_
90-38	16143-16144	a	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder
90-39	16145-16154	covariate	_	_
90-40	16154-16155	.	_	_

91-1	16156-16157	A	_	_
91-2	16158-16176	Greenhouse‐Geisser	_	_
91-3	16177-16187	correction	_	_
91-4	16188-16191	was	_	_
91-5	16192-16199	applied	_	_
91-6	16200-16204	when	_	_
91-7	16205-16215	Mauchley's	_	_
91-8	16216-16226	assumption	_	_
91-9	16227-16229	of	_	_
91-10	16230-16240	sphericity	_	_
91-11	16241-16244	was	_	_
91-12	16245-16253	violated	_	_
91-13	16253-16254	.	_	_

92-1	16255-16256	A	_	_
92-2	16257-16267	Bonferroni	_	_
92-3	16268-16278	correction	_	_
92-4	16279-16282	for	_	_
92-5	16283-16286	the	_	_
92-6	16287-16290	six	_	_
92-7	16291-16299	separate	_	_
92-8	16300-16304	ROIs	_	_
92-9	16305-16312	results	_	_
92-10	16313-16315	in	_	_
92-11	16316-16317	a	_	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging
92-12	16318-16330	significance	_	_
92-13	16331-16336	value	_	http://maven.renci.org/NeuroBridge/neurobridge#Pyromania
92-14	16337-16339	of	_	_
92-15	16340-16341	p	_	_
92-16	16341-16342	 	_	_
92-17	16342-16343	<	_	_
92-18	16343-16344	 	_	_
92-19	16344-16349	0.008	_	_
92-20	16350-16353	for	_	_
92-21	16354-16358	this	_	_
92-22	16359-16367	analysis	_	_
92-23	16367-16368	.	_	_

93-1	16369-16376	However	_	_
93-2	16376-16377	,	_	_
93-3	16378-16382	this	_	_
93-4	16383-16385	is	_	_
93-5	16386-16387	a	_	_
93-6	16388-16400	conservative	_	_
93-7	16401-16409	approach	_	_
93-8	16409-16410	,	_	_
93-9	16411-16416	which	_	_
93-10	16417-16420	may	_	_
93-11	16421-16427	result	_	_
93-12	16428-16430	in	_	_
93-13	16431-16436	false	_	_
93-14	16437-16446	negatives	_	_
93-15	16446-16447	.	_	_

94-1	16448-16455	Results	_	_
94-2	16456-16459	are	_	_
94-3	16460-16469	therefore	_	_
94-4	16470-16478	reported	_	_
94-5	16479-16490	significant	_	_
94-6	16491-16493	at	_	_
94-7	16494-16495	p	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
94-8	16495-16496	 	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
94-9	16496-16497	<	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
94-10	16497-16498	 	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
94-11	16498-16502	0.05	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
94-12	16503-16507	with	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
94-13	16508-16515	results	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
94-14	16516-16525	surviving	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
94-15	16526-16536	Bonferroni	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
94-16	16537-16547	correction	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
94-17	16548-16559	highlighted	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders	http://maven.renci.org/NeuroBridge/neurobridge#StructuredClinicalInterviewforDSMDisorders
94-18	16559-16560	.	_	_

95-1	16562-16565	ROI	_	_
95-2	16566-16570	BOLD	_	_
95-3	16571-16577	signal	_	_
95-4	16578-16582	time	_	_
95-5	16583-16589	course	_	_
95-6	16590-16593	and	_	_
95-7	16594-16604	subjective	_	_
95-8	16605-16611	rating	_	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
95-9	16612-16616	time	_	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
95-10	16617-16623	course	_	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholUseDisordersIdentificationTest
95-11	16624-16632	temporal	_	_
95-12	16633-16644	correlation	_	_
95-13	16645-16653	analysis	_	_
95-14	16654-16656	In	_	_
95-15	16657-16669	participants	_	_
95-16	16670-16679	reporting	_	_
95-17	16680-16681	a	_	_
95-18	16682-16692	subjective	_	_
95-19	16693-16699	rating	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse	http://maven.renci.org/NeuroBridge/neurobridge#AlcoholAbuse
95-20	16700-16706	change	_	_
95-21	16707-16709	in	_	_
95-22	16710-16718	response	_	_
95-23	16719-16721	to	_	_
95-24	16722-16725	the	_	_
95-25	16726-16730	drug	_	_
95-26	16731-16734	cue	_	_
95-27	16735-16742	session	_	_
95-28	16742-16743	,	_	_
95-29	16744-16746	we	_	_
95-30	16747-16759	investigated	_	_
95-31	16760-16767	whether	_	http://maven.renci.org/NeuroBridge/neurobridge#DissociativeDrugHarmfulUse
95-32	16768-16773	their	_	http://maven.renci.org/NeuroBridge/neurobridge#DissociativeDrugHarmfulUse
95-33	16774-16784	subjective	_	_
95-34	16785-16791	rating	_	_
95-35	16792-16796	time	_	_
95-36	16797-16803	course	_	_
95-37	16804-16807	was	_	_
95-38	16808-16818	temporally	_	_
95-39	16819-16829	correlated	_	_
95-40	16830-16834	with	_	_
95-41	16835-16839	fMRI	_	_
95-42	16840-16846	signal	_	_
95-43	16847-16849	in	_	_
95-44	16850-16853	the	_	_
95-45	16854-16858	ROIs	_	_
95-46	16858-16859	.	_	_

96-1	16860-16868	Analyses	_	_
96-2	16869-16873	were	_	_
96-3	16874-16884	restricted	_	_
96-4	16885-16887	to	_	_
96-5	16888-16898	subjective	_	_
96-6	16899-16906	ratings	_	_
96-7	16907-16910	and	_	_
96-8	16911-16914	ROI	_	_
96-9	16915-16919	BOLD	_	_
96-10	16920-16926	signal	_	_
96-11	16927-16931	time	_	_
96-12	16932-16939	courses	_	_
96-13	16939-16940	,	_	_
96-14	16941-16954	demonstrating	_	_
96-15	16955-16966	significant	_	_
96-16	16967-16974	effects	_	_
96-17	16975-16977	in	_	_
96-18	16978-16981	the	_	_
96-19	16982-16988	ANOVAs	_	_
96-20	16988-16989	.	_	_

97-1	16990-16996	Before	_	_
97-2	16997-17009	correlations	_	_
97-3	17010-17014	were	_	_
97-4	17015-17022	carried	_	_
97-5	17023-17026	out	_	_
97-6	17026-17027	,	_	_
97-7	17028-17031	the	_	_
97-8	17032-17041	pre‐video	_	_
97-9	17042-17050	baseline	_	_
97-10	17051-17061	subjective	_	_
97-11	17062-17068	rating	_	_
97-12	17069-17072	was	_	_
97-13	17073-17083	subtracted	_	_
97-14	17084-17088	from	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
97-15	17089-17093	each	_	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
97-16	17094-17099	video	_	_
97-17	17100-17103	and	_	_
97-18	17104-17114	post‐video	_	_
97-19	17115-17121	rating	_	_
97-20	17122-17125	for	_	_
97-21	17126-17130	each	_	_
97-22	17131-17138	session	_	_
97-23	17138-17139	.	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	_

98-1	17140-17143	The	_	_
98-2	17144-17151	neutral	_	_
98-3	17152-17159	session	_	_
98-4	17160-17167	ratings	_	_
98-5	17168-17172	were	_	_
98-6	17173-17177	then	_	_
98-7	17178-17188	subtracted	_	_
98-8	17189-17193	from	_	_
98-9	17194-17197	the	_	_
98-10	17198-17202	drug	_	_
98-11	17203-17206	cue	_	_
98-12	17207-17214	session	_	_
98-13	17215-17222	ratings	_	_
98-14	17222-17223	.	http://maven.renci.org/NeuroBridge/neurobridge#FunctionalMagneticResonanceImaging	_

99-1	17224-17228	This	_	_
99-2	17229-17232	was	_	_
99-3	17233-17235	to	_	_
99-4	17236-17242	ensure	_	_
99-5	17243-17247	both	_	_
99-6	17248-17251	the	_	_
99-7	17252-17256	fMRI	_	_
99-8	17257-17260	and	_	_
99-9	17261-17271	subjective	_	_
99-10	17272-17278	rating	_	_
99-11	17279-17283	data	_	_
99-12	17284-17293	reflected	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
99-13	17294-17298	drug	http://maven.renci.org/NeuroBridge/neurobridge#TaskParadigmImaging	http://maven.renci.org/NeuroBridge/neurobridge#BackTaskTest
99-14	17299-17302	cue	_	_
99-15	17303-17310	session	_	_
99-16	17311-17318	changes	_	_
99-17	17319-17323	from	_	_
99-18	17324-17332	baseline	_	_
99-19	17333-17338	minus	_	_
99-20	17339-17346	neutral	_	_
99-21	17347-17354	session	_	_
99-22	17355-17362	changes	_	_
99-23	17363-17367	from	_	_
99-24	17368-17376	baseline	_	_
99-25	17377-17378	(	_	_
99-26	17378-17382	fMRI	_	_
99-27	17383-17387	data	_	_
99-28	17388-17395	already	_	_
99-29	17396-17398	in	_	_
99-30	17399-17403	this	_	_
99-31	17404-17410	format	_	_
99-32	17411-17416	after	_	_
99-33	17417-17428	first‐level	_	_
99-34	17429-17437	analysis	_	_
99-35	17437-17438	)	_	_
99-36	17438-17439	.	_	_

100-1	17440-17447	Finally	_	_
100-2	17447-17448	,	_	_
100-3	17449-17452	the	_	_
100-4	17453-17457	fMRI	_	_
100-5	17458-17462	BOLD	_	_
100-6	17463-17469	signal	_	_
100-7	17470-17474	data	http://maven.renci.org/NeuroBridge/neurobridge#NoKnownDisorder	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
100-8	17475-17479	were	_	http://maven.renci.org/NeuroBridge/neurobridge#ParallelGroupTrial
100-9	17480-17488	averaged	_	_
100-10	17489-17493	over	_	_
100-11	17494-17495	3	_	_
100-12	17495-17496	‐	_	_
100-13	17496-17502	minute	_	_
100-14	17503-17512	intervals	_	_
100-15	17513-17515	to	_	_
100-16	17516-17523	reflect	_	_
100-17	17524-17527	the	_	_
100-18	17528-17529	3	_	_
100-19	17529-17530	‐	_	_
100-20	17530-17536	minute	_	_
100-21	17537-17545	interval	_	_
100-22	17546-17548	of	_	_
100-23	17549-17559	subjective	_	_
100-24	17560-17566	rating	_	_
100-25	17567-17579	presentation	_	_
100-26	17580-17586	during	_	_
100-27	17587-17591	each	_	_
100-28	17592-17599	session	_	_
100-29	17599-17600	.	_	_

101-1	17601-17614	Correlational	_	_
101-2	17615-17623	analyses	_	_
101-3	17624-17628	were	_	_
101-4	17629-17636	carried	_	_
101-5	17637-17640	out	_	_
101-6	17641-17648	between	_	_
101-7	17649-17653	each	_	_
101-8	17654-17666	individual's	_	_
101-9	17667-17677	subjective	_	_
101-10	17678-17684	rating	_	_
101-11	17685-17688	and	_	_
101-12	17689-17692	ROI	_	_
101-13	17693-17697	BOLD	_	_
101-14	17698-17704	signal	_	_
101-15	17705-17709	time	_	_
101-16	17710-17717	courses	_	_
101-17	17718-17723	using	_	_
101-18	17724-17733	Pearson's	_	_
101-19	17734-17741	product	_	_
101-20	17742-17748	moment	_	_
101-21	17749-17760	correlation	_	_
101-22	17761-17772	coefficient	_	_
101-23	17772-17773	.	_	_

102-1	17774-17783	Resultant	_	_
102-2	17784-17795	correlation	_	_
102-3	17796-17808	coefficients	_	_
102-4	17809-17813	were	_	_
102-5	17814-17822	Fisher's	_	_
102-6	17823-17836	z‐transformed	_	_
102-7	17837-17840	and	_	_
102-8	17841-17848	entered	_	_
102-9	17849-17853	into	_	_
102-10	17854-17864	one‐sample	_	_
102-11	17865-17872	t‐tests	_	_
102-12	17873-17875	to	_	_
102-13	17876-17885	determine	_	_
102-14	17886-17891	group	_	_
102-15	17892-17897	level	_	_
102-16	17898-17910	significance	_	_
102-17	17910-17911	.	_	_







































































































